Back to Search Start Over

Effect of tibolone and raloxifene on serum markers of apoptosis in postmenopausal women.

Authors :
Lambrinoudaki, I.
Karaflou, M.
Kaparos, G.
Alexandrou, A.
Creatsa, M.
Aravantinos, L.
Augoulea, A.
Kouskouni, E.
Source :
Climacteric. Apr2013, Vol. 16 Issue 2, p258-264. 7p.
Publication Year :
2013

Abstract

Objectives To investigate the effect of tibolone and raloxifene on the serum apoptotic markers soluble Fas (sFas), soluble Fas ligand (sFasL) and cytochrome-c (cyt-c) in postmenopausal women. Methods A total of 89 healthy postmenopausal women, attending the University Menopause Clinic, were randomly allocated to tibolone ( n =30), raloxifene ( n =29) or no treatment ( n =30). Serum apoptotic markers sFas, sFasL and cyt-c were measured at baseline and at 6 months. Results Serum sFasL decreased significantly in women receiving tibolone (baseline: 53.8±28.3 pg/ml, 6 months: 40.45±19.2 pg/ml, p =0.001), whilst sFas levels did not significantly change in this group. Serum sFas or sFasL did not change either in the raloxifene group or in the control group. Serum cyt-c concentrations were under the detection limit of the assay in all women assessed. Conclusions Tibolone use resulted in a significant decrease in serum sFasL, but not in serum sFas. Raloxifene had no effect on either sFas or sFasL. These results may indicate that tibolone use is associated with a decrease in receptor-mediated apoptosis. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
13697137
Volume :
16
Issue :
2
Database :
Academic Search Index
Journal :
Climacteric
Publication Type :
Academic Journal
Accession number :
86059791
Full Text :
https://doi.org/10.3109/13697137.2012.668251